Open AccessReal-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
Author(s) -
Bader Alshamsan,
Ahmed Badran,
Aisha Alshibany,
Fatma Maraiki,
Mahmoud A. Elshenawy,
Tusneem Elhassan,
Jean Paul Atallah
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s323499
Subject(s) - pazopanib , medicine , soft tissue sarcoma , oncology , common terminology criteria for adverse events , sarcoma , adverse effect , interquartile range , hazard ratio , tolerability , odds ratio , confidence interval , progression free survival , surgery , chemotherapy , cancer , pathology , sunitinib
Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS.